Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
10.46
-0.11 (-1.04%)
Aug 14, 2025, 1:42 PM - Market open
Nurix Therapeutics Revenue
Nurix Therapeutics had revenue of $44.06M in the quarter ending May 31, 2025, with 264.34% growth. This brings the company's revenue in the last twelve months to $88.38M, up 41.86% year-over-year. In the fiscal year ending November 30, 2024, Nurix Therapeutics had annual revenue of $54.55M, down -29.15%.
Revenue (ttm)
$88.38M
Revenue Growth
+41.86%
P/S Ratio
9.53
Revenue / Employee
$309,024
Employees
286
Market Cap
799.66M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NRIX News
- 4 weeks ago - Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors - Seeking Alpha
- 5 weeks ago - Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 5 weeks ago - European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia - GlobeNewsWire
- 2 months ago - Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM) - GlobeNewsWire
- 2 months ago - Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025) - GlobeNewsWire
- 2 months ago - Sanofi Exercises License Extension Option to Nurix's STAT6 Program - GlobeNewsWire
- 2 months ago - Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire